ProfileGDS5678 / 1417469_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 6% 39% 6% 8% 6% 6% 6% 35% 6% 6% 6% 6% 6% 6% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.137396
GSM967853U87-EV human glioblastoma xenograft - Control 22.8794339
GSM967854U87-EV human glioblastoma xenograft - Control 32.129426
GSM967855U87-EV human glioblastoma xenograft - Control 42.150738
GSM967856U87-EV human glioblastoma xenograft - Control 52.070946
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.17126
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.137226
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7814335
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.094846
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.112686
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.109716
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.102796
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.112816
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.111816